Science Driven by People, Powered by Expertise
Meet the experts advancing vivoPharm’s research excellence
Dr. Ralf Brandt
Is a distinguished pharmaceutical and oncology research executive with over 30 years of experience in drug discovery, oncology, angiogenesis, and preclinical development. He has held senior leadership roles including CEO and Founder of vivoPharm Pty Ltd and vivoPharm Global Pty Ltd, President Discovery at CGIX and VYANT Bio Inc. , and executive positions at Novartis and Bionomics Ltd. Dr. Brandt has advanced more than 50 compounds to clinical studies by generating and presenting non-clinical data to client and/or regulatory bodies, holds five international patents, and authored 27 peer-reviewed publications and several book chapters. He is an expert in in vivo and in vitro pharmacology, cell biology, animal model development, GLP compliance, and translational research, and serves on several scientific advisory boards globally. He earned his PhD in Biochemistry from the Max-Delbrück Center for Molecular Medicine, Berlin, and has received multiple awards including the prestigious Fogarty Fellowship (NIH, USA).
Prof. Dr. Klaus Kutz
Is a German physician and consultant with over 25 years of independent experience in Clinical Pharmacology and Drug Safety, following 12 years in senior international roles at Sandoz and Sanofi. As founder of AccelPharm, he supports small and mid-sized pharmaceutical companies and CROs in early clinical development, regulatory submissions (INDs, NDAs), and safety oversight. His therapeutic expertise spans oncology, cardiovascular disease, gastroenterology, metabolism, neurology, dermatology, and pharmacotherapy in the elderly. A Professor of Medicine at the University of Bonn, he is board-certified in Internal Medicine, Gastroenterology, and Clinical Pharmacology, and fluent in German, English, and French.
Rosemary Bubner
Is an experienced Scientific Writer with a strong background in pharmaceutical quality assurance and drug analysis. She began her career as a Microbiologist and Laboratory Analyst at Faulding Pharmaceuticals, working to GLP standards in bioequivalence and QA laboratories. Since 2006, she has worked at vivoPharm Pty Ltd, specializing in the preparation of detailed preclinical study reports. Rosemary holds a Bachelor of Applied Science (Medical Technology) from the South Australian Institute of Technology and has completed extensive GLP compliance training.
Dr. Neeta Mathuria
Is a highly experienced Quality Assurance and Preclinical Research professional with over 15 years in toxicology, pharmacology, efficacy testing, and GLP compliance in CROs and pharmaceutical companies. She began her career as a Study Director and later transitioned to Quality Assurance leadership, including her role as Manager – QA at Bharat Serums and Vaccines.
Dr. Mathuria has extensive expertise in OECD GLP, GMP, regulatory compliance, preclinical study audits, SOP implementation, and staff training. She holds a PhD in Zoological Sciences and multiple degrees in Zoology and Education, and has received recognition as Best Scientist and Preclinical Best Research Scientist. She is also an active researcher, reviewer, and editorial board member for international journals.
Dr. Vinod Kumar
Is a seasoned research and development professional with over 18 years of experience across preclinical research, translational science, and early-phase clinical development in global CRO and academic environments.
He currently serves as an Adjunct Senior Fellow at The University of Queensland, leading research in the preclinical development of neuroprotective therapeutics and advanced pharmacokinetic, metabolomic, proteomic, and lipidomic studies.
Dr. Kumar holds a PhD in Drug Development and Pharmacokinetics and brings proven expertise in bioanalytical method validation, in vivo study design, and regulatory compliance. His career includes leadership and technical roles at The University of Queensland, Douglas Pharmaceuticals, and the Auckland Cancer Society Research Centre, reflecting a strong track record in scientific innovation and operational excellence.
Recognised for his depth of knowledge in LC-MS/MS method validation and PK/TK analysis, Dr. Kumar has successfully supported programs involving small molecules, biologics, nanoparticles, and liposomal formulations. He excels at bridging scientific strategy with clinical execution—accelerating the transition from discovery to human studies.